Sunday, March 6, 2016

TNXP Awaits Data In Q2, LLY Uncovers Ixekizumab's Potential, High Five For MNOV

MediciNova Inc.'s (MNOV) phase II trial results of MN-166 (ibudilast) in opioid dependence have been encouraging.

from RTT - Biotech http://ift.tt/1LL0tkG
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)